Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth ...
Zacks.com on MSN1h
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded DealThis week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Zacks.com on MSN23h
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With TevaShares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback